Literature DB >> 3051743

[Ludwig Haberlandt (l885-l932) and the development of hormonal contraception].

W D Müller-Jahncke1.   

Abstract

Ludwig Haberlandt, physiologist in Innsbruck, tried in the late twenties to develop hormonal contraceptives based on sexhygienic ideas of Sigmund Freud. Although the chemical-physiological knowledge of that time encouraged this plan, after Haberlandt's death in 1932 his tests were dropped and forgotten. It was after World War II, when research in this field was begun in the USA by Gregory Pincus, supported by "Planned Parenthood Federation" under leading of Margret Sanger. Although clinical tests proved to be successful, restrictive social-political conditions in the fifties delayed this project considerably. But in 1958 the first Anti-Baby-Pill reached the US-market.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3051743

Source DB:  PubMed          Journal:  Z Gesamte Inn Med        ISSN: 0044-2542


  4 in total

1.  Ludwig Haberlandt--A pioneer in hormonal contraception.

Authors:  Edda Haberlandt
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities.

Authors:  Andrea Heinzlmann; Katalin Köves; György M Nagy
Journal:  Endocrine       Date:  2010-03-30       Impact factor: 3.633

3.  Possible Effect of Extended Use of Hormonal Contraception on Increased Levels of Antiphospholipid Antibodies in Infertile Women.

Authors:  Z Ulcova-Gallova; K Bibkova; Z Micanova; P Losan; K Babcova
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

4.  Sexual dimorphism in the effect of concomitant progesterone administration on changes caused by long-term estrogen treatment in pituitary hormone immunoreactivities of rats.

Authors:  Andrea Heinzlmann; Katalin Koves; Magdolna Kovacs; Valer Csernus
Journal:  Med Sci Monit       Date:  2011-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.